Minnesota Mining and Manufacturing Company

3m Innovative Properties Company

Reva Medical, Inc.

Dura Pharmaceuticals, Inc.

Elan Pharmaceuticals, Inc.

Riker Laboratories Inc.

3m Company

Robert K Schultz

David W Schultz

Donald K Brandom

Robert A Moris

Danna L Ross

Eric V Schmid

James E McGrath

Joan Zeltinger

Tsi-Zong Tzou

Mark Kevitt Debe

John Charles Clark

Robert F Eisele

Philip A Jinks

Malcolm Hill

Lioubov Kabalnova

Gary H Ward

Ernest G Baluca

Stephen M Berge

Joseph M Beaurline

Constantinos Sioutas

Clyde Witham

Martin J Oliver

Harry E Johnson

Jessica Earley

Stephen N Quessy

Durgadas Bolikal

The present application provides polymer materials having the desired properties for implantation into a human or animal body, in particular, biocompatibility, biodegradability, radiopacity and mechanical properties. Methods of making such polymer materials, compositions or devices comprising such polymer materials, and uses of such polymer materials, compositions and devices are also disclosed.

Cross-linked radiopaque bioresorbable polymers and devices made therefrom

Side-chain crystallizable (SCC) polymers are useful in various medical applications. In certain applications, heavy atom containing side-chain crystallizable polymers (HACSCCP's) are particularly useful. An example of a HACSCCP is a polymer that comprises a main chain, a plurality of crystallizable side chains, and a plurality of heavy atoms attached to the polymer. In certain configurations, the heavy atoms are present in an amount that is effective to render the polymer radiopaque. A polymeric material that includes an HACSCCP may be fabricated into a medical device useful for at least partially occluding a body cavity. For example, such a medical device may be an embolotherapy product. A polymeric material that includes a SCC polymer may also be fabricated into other medical devices, such as stents.

Side-chain crystallizable polymers for medical applications

The present invention relates to oil-based formulations of hydrophobic drugs for the uniform coating of medical devices such as vascular stents and balloons. Another aspect of the present invention is an intravascular medical device having an oil-based coating suitable for delivering a water-insoluble drug, comprising one or more of an anti-oxidant, an anti-inflammatory and an anti-restenotic agent.

Drug formulations for coating medical devices

Pharmaceutical suspension aerosol formulations containing a therapeutically effective amount of a drug and HFC 134a, HFC 227, or a mixture thereof.

Suspension aerosol formulations

Pharmaceutical suspension aerosol formulations containing a therapeutically effective amount of a drug and HFC 134 , HFC 227, or a mixture thereof.

In a powder formulation for use in a dry powder inhaler, a pharmaceutical acts as its own carrier, so that use of lactose or other excipients are not needed. The dry powder formulation has a single active pharmaceutical compound having two major populations in particle size distribution: microfine particles of the active pharmaceutical, of 1-10 microns in diameter, and larger carrier particles, also of the active pharmaceutical compound. The carrier particles provide a long acting, delayed onset, and optionally therapeutic effect via the GI tract, while the microfine particles provide a fast onset effect via the lung.

Method for pulmonary and oral delivery of pharmaceuticals

Pharmaceutical solution aerosol formulations comprising beclomethasone 17,21 dipropionate, ethanol, and a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane, and a mixture thereof.

Method of forming conductive lines

A method for inhalation of a dry powder drug includes the steps of providing a dry powder drug composition having a drug particle size of from about 1-7 microns and a mass median aerodynamic diameter of the delivered aerosol of from about 3.5 to 5.5 microns. This composition is loaded into an inhaler which is generally flow rate independent, and with the inhaler having an inspiration flow resistance of about 0.12 to 0.21 (cmH.sub.2 O).sup.1/2 over the range of about 15-60 L/min. The patient inhales the drug composition from the inhaler with an inspiration flow rate of about 15-60 L/min, resulting in a delivery efficiency measured by respirable fraction greater than 20%.

Methods of dry powder inhalation

Pharmaceutical aerosol formulations comprising flunisolide, ethanol, and a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane, and a mixture thereof.

Flunisolide aerosol formulations

A hand held aerosol actuator involving an aerosol source and a chamber having walls defining a constriction aperture. The aerosol source communicates with the chamber and directs an aerosol dose along an axis into the chamber. The constriction aperture is coaxial with the exit orifice and is dimensioned such that the respirable mass of the aerosol dose is increased relative to the respirable mass of an aerosol dose expelled through a like actuator not having the constriction aperture.

Aerosol actuator

Beclomethasone solution aerosol formulations

Pharmaceutical aerosol formulations substantially free of chlorofluorocarbons and comprising a therapeutically effective amount of flunisolide in solution with ethanol and a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and a mixture thereof are used for the treatment of bronchial asthma. The formulation may be delivered by a metered dose inhaler with a canister that is inert to flunisolide.

Low energy surfaces based on nanostructured films exhibit advancing and receding contact angles for liquids such that (1) the difference between the advancing and receding contact angles approaches zero and (2) the advancing and receding contact angles approach 180.degree.. The low energy surface of the present invention comprises a nanostructured film coated with an organized molecular assembly (OMA). Advantageously, the chemical and wetting characteristics of the surface can be altered by changing the functionality of the OMA end groups exposed to the environment in contact with the surface of the nanostructured film.

Growing community of inventors

Poway, CA, United States of America

Robert K Schultz